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Introduction  
This bachelor project was about investigating new synthetic routes for metal complexes that 
are potential anti-malarial agents. The testing for anti malarial activity is to be carried out 
after the end of this project. The focus will thus be on presenting the laboratory work that was 
achieved; some synthetic strategies that can be used and further developed and some that 
should be avoided when synthesizing these kinds of metal complexes.  
It is believed that four different metal complexes with potential anti-malaria activity were 
successfully synthesized, of which two were pure and two needs further purification. 
This report describes the synthesis and structures of for the ligands L’ L1, HL2 and HL3 that 
were used in the attempted syntheses to form the different complexes. The routes for making 
the complexes (1) – (5) are thought to have been successful (complex (3) was an intermediate) 
and the desired complexes (6) – (10) could not be synthesized.  
Metal drugs 
Metal-containing drugs are a relatively new field in medicine, and today it is uncommon for a 
drug to contain any metal. There are, however, a few exceptions; Sodium aurothiomalate is a 
gold-containing drug used for treating rheumatoid arthritis, and the drug cisplatine, which 
contains platinum, is used in cancer treatment. 
When a pathogenic organism has developed resistance to a drug the drug needs to be modified 
to overcome the resistance. One way of modification could be the addition of a metal. Since 
so few drugs today contains metal they could indeed be modified by adding one. It is 
therefore not unlikely that more and more metal containing drugs will be synthesized and 
tested in the future. 
 
 
Figure 1. Examples of metal containing drugs, the anti-cancer agent cis-platin (left) and rheumatoid treatment sodium 
aurothiomalate (right). 
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Malaria 
A parasitic disease 
Malaria is caused by protozoan parasites of the genus Plasmodium. Five types are known to 
infect humans; Plasmodium falciparum, Plasmodium vivax, Plasmodium malarie, 
Plasmodium ovale and Plasmodium knowlesi.
1
 The lifecycle of the parasite is quite complex. 
It begins with a mosquito biting a vertebrate host (i.e. a human). From the mosquito´s saliva 
so called sporozoites are released into the blood and transported to the liver where they invade 
liver cells and produce merozoites. After several days the liver cells burst, releasing thousands 
of merozoites that invade red blood cells. Inside the red blood cells they digest hemoglobin, 
using its amino acids as building blocks to develop new merozoites through asexual 
reproduction. Eventually the cells burst, releasing a new wave of merozoites to invade new 
red blood cells. This cycle goes on and on, and every time it reaches the step of bursting blood 
cells the infected vertebrate develops flue like symptoms like fever, vomiting and joint pain. 
Some merozoites develop further into gametocytes, which can be either male or female. When 
a mosquito bites the host the gametocytes can be taken up and multiply through sexual 
reproduction in the mosquito´s gut. If the mosquito already carries a strain of gametocytes 
these two will mate, giving rise to a new strain of parasites. The offspring will undergo 
several transformations and is eventually developed to sporozoites, which can enter a host via 
a mosquito bite and complete the life cycle.
2
 Since Plasmodium parasites are able to 
reproduce sexually they have a much larger diversity in their gene pool compare to bacteria, 
and are therefore more likely to develop drug resistance.       
The WHO World Malaria Report from 2014 states that there has been great progress in the 
fight against malaria during the 21th century. According to the report the mortality rate has 
decreased by 47 % globally and 54 % in the WHO African Region between 2000 and 2013, 
which is believed to be an effect of increased political commitment and expansion of global 
malaria investments. These two factors have lead to improvement in mosquito control, 
diagnostic testing and treatment with artermisinin-based combination therapies (ACT:s). 
However, the report also states that parasite resistance to drugs is of great concern, and that 
malaria is still responsible for 430 000 child deaths each year.
 3
  Since more and more 
parasites develop resistance to drugs that are now used it is crucial to come up with new drugs 
to overcome the resistance. 
Malaria drugs 
As mentioned, the parasite digests red blood cells to use their amino acids for growth and 
reproduction. When doing so the iron in the hemoglobin gets oxidized from Fe
2+
 to Fe
3+
. The 
oxidized heme is called ferric heme and is poisonous for organisms, since it can react with 
various parts of the cell. The human body protects itself from this by using an enzyme that the 
malaria parasite does not have. Instead the parasite has a different way of protecting itself 
                                                          
1
 Warrell,  D. A. Oxford Text Book of Medicine, Fifth edition. 7.8.2 Malaria. Latest Update - November 2011 
2
 Greenwood, B. M.; Fidock, D. A.; Kyle, D. E.; Kappe, S. H. I.; Alonso, P. L.; Collins, F. H.; Duffy J. Clin. Invest., 
2008, 1136, 32.  
3
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from the ferric heme; the hemoglobin is digested in an organelle called the food vacuole, and 
in this vacuole the poisonous ferric heme gets crystallized into a non-toxic substance called 
hemozoin. Some successful malaria drugs have this heme crystallization as a target. These 
types of drugs enter the vacuole, accumulate and prevent the formation of hemozoin. The 
parasite then dies from poisoning by ferric heme. 
One example is the drug chloroquine (Figure 2), which was discovered in 1934 and widely 
used since WWII. It is a quite hydrophobic molecule and can therefore enter the food vacuole 
through the hydrophobic vacuole membrane wall, and since the food vacuole is highly acidic 
the chloroquine gets protonated. This makes it a lot more hydrophilic and prevents it from 
exiting the vacuole through the membrane wall. Within the vacuole chloroquine interacts with 
the iron(III) in ferric heme and thereby prevents the formation of hemozoine. 
 
 
Figure 2. Structure and active sites in the anti malaria drug chloroquine. Adapted from Glans (2012).
4
  
Due to massive global use of choloquine most of the malaria parasites today have developed 
some or complete resistance against chloroquine. It is believed that this is caused by a 
mutation in a transport protein, which makes the protein more hydrophilic. The protein can 
then interact with the protonated and hydrophilic cholorioquine
5,6
, which then gets transported 
out of the food vacuole. 
In order to overcome this resistance a huge number of modified chloroquine molecules have 
been synthesized. Biot et al linked the chloroquine to a ferrocene, creating the molecule 
ferroquine (Figure 3).
7
 Ferroquine overcomes the chloroquine resistance and has now 
completed Phase IIb clinical trials.
8
 It is therefore most interesting to come up with new 
similar, metal-containing molecules to test for anti-malaria activity. 
                                                          
4
 Glans L. Organometallic complexes with antimalarial properties, Doctoral Thesis, Lund University, Sweden, 
2012. 
5
 Hyde, J. E. FEBS Journal, 2007, 274, 4688 
6
 Lakshmanan, V.; Bray, P. G.; Verdier-Pinard, D.; Johnson, D. J.; Horrocks, P.; Muhle, R. A.; Alakpa, G. E. Hughes, 
R. H.; Wars, S. A.; Krogstad, D. J.; Sidhu, A. B. S.; Fidock, D. A. EMBO J 2005, 24, 2294 
7
 Biot, C.; Dive, D.; Medical Organometallic Chemistry, eds Jaouen G and Meltzer-Nolte N, Springer, 2010, pp. 
155-194 
8
 https://clinicaltrials.gov/ct2/show/NCT00988507?term=ferroquine&rank=1 , updated June 27 2011 
6 
 
 
Figure 3. Picture of ferroquine.  
Other malaria drugs 
According to the WHO World Malaria Report from 2014 artemisine and its semisynthetic 
derivatives are the most important malaria drugs today, but growing resistance to these makes 
it important to come up with new drugs. Except the emerging resistance, a major drawback 
with artemisinin is that it is synthesized by modifying extracted plant material, which makes it 
highly expensive compare to chloroquinoline.
9
 The full of action mechanism of artemisinin is 
a subject of debate.
3
  
The oldest, and still an effective malaria drug, is quinine. It is found in the bark of the 
Cinchona tree, which is native to the Andes, and still today the tree remains the only 
economically practical source of quinine. A drawback with this drug is that it exhibits many 
unpleasant side effects, which is a motivation to come up with alternatives. Quinine is almost 
only used to for treatment when no other drugs work and the patent risks dying from the 
malaria infection.  As can be seen on the structure, chloroquine resembles quinine. 
 
Figure 4. Structure of the anti-malaria agent artemisinin. 
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 Eastman, R. T.; Fidock, D. A. Nat. Rev.Microbiol.,2009, 7, 864. 
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Figure 5: Structure of the anti-malaria quinine. The newer drug chloroquine resembles of this molecule.  
Tuberculosis 
Tuberculosis (TB) is a disease caused by various strains of mycobacteria, which typically 
infect the lungs. This leads to chronic cough, bleeding lungs and fever. One third of the 
world’s population is believed to be or have been infected with TB, however not all these 
cases lead to any symptoms. An infection can however develop to active disease with the 
mentioned symptoms and 9 million people had active TB in 2013, of which 1.5 million died 
of the disease
10
.  
There are different types of drugs against TB, which needs to be combined to for effective 
treatment. One of these drugs is pyrazinamide (PZA). It is never taken on its own, but still it is 
an important drug for the treatment of TB since it is used in combination with other drugs. TB 
causes most problems for poor people in development countries like the WHO African 
Region because the lack of sufficient hygiene and AIDS makes it more likely to develop 
active TB. Since both malaria and tuberculosis causes problems in the same areas it would be 
useful to have a drug that can be used to treat both diseases. The ligand L
1
 was synthesized 
and used in the synthesis of some metal complexes. As can be seen when looking at its 
structure, it both has a part resembling of chloroquine and a part for anti-TB activity (PZA). 
 
Figure 6. Pyrazinamide, a drug used in combination with other drugs in the treatment of tuberculosis.  
The ultimate result for this project would be to synthesize a drug that would overcome the 
chloquine resistance of malaria due to the addition of a metal, and also work as a treatment for 
tuberculosis when combined with other TB drugs. 
                                                          
10
 WHO Global Tuberculosis report 2014, World Health Organization, Geneva, 2014 
8 
 
Complexes  
General 
The metals ruthenium (Ru), rhodium (Rh) and rhenium (Re) were used in the attempts of 
making the metal complexes along with the ligands L
1
, HL
2
 and HL
3
 which are presented in 
Figure 7. All ligands were synthesized by the precursor L’. L3 is a reduced form of L2 and 
was used only in a few unsuccessful experiments. In all the synthetic attempts with HL
2 
and 
HL
3 
a base was used to deprotonate the desired ligand into [L
2
]
 –
 or [L
3
]
- 
, to make them able 
to coordinate to the metal. The base was either triethylamine or KOH. All three ligands are 
bidentate, meaning that they interact with the metal from two different sites of the ligand; 
bidentate can roughly be translated at “two toothed”, meaning that the ligand “bites” from two 
directions. 
Figure 7. Chemical structures of the ligands L
1
, HL
2
 and HL
3
. The synthesis of all ligands started from L’. 
So, what reason is there for a complex to actually form? The main answer to the question 
could be described by the so called chelate effect: When a bidentate ligand interacts with the 
metal in a solution the metal loses two monodentate ligands (Figure 8). Thus one molecule 
has been taken up and two released, which gives the net change of one molecule. The entropy 
of mixing is therefore increased, making the Gibbs free energy of the mixture lower. This 
should favor the reaction and drive it towards a state where the bidentate ligand interacts with 
the metal and the monodentate ligands have gone into solution. The chelate effect is thus an 
entropic effect. 
 
Figure 8. A metal complex consisting of solely monodentate ligands reacts with a bidentate ligand. The entropy increases 
as one molecule is taken up at the same time as two are released from the metal.   
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Previous work 
Previous syntheses of metal complexes that have potential anti-malaria activity have been 
carried out by the Nordlander Group of Lund Univerity. A large amount of work is described 
by Glans
3
, while other results have not yet been published. The complexes (1) – (11) that are 
presented in this bachelor thesis differ from the previous complexes because they are not 
based on half sandwiched structure. Figure 5 shows examples of previous synthesized half 
sandwich complexes containing the ligands L
1 
and HL
2
, the same ligands that were used in 
this bachelor project. The complexes containing ruthenium and osmium are presented by 
Glans
3
, while the other four have not yet been published. 
 
Figure 9.  Examples of half sandwich complexes of L1 and L2 already synthesized in the Nordlander Group.   
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Ruthenium 
Two ruthenium starting materials were used: RuCl2(DMSO)4, where ruthenium has the 
oxidation number 2, and RuCl3 x H2O, where ruthenium is in the +3 as oxidation state. 
It was attempted to react both L
1
 and HL
2
 with RuCl2(DMSO)4 under various conditions in 
order to form new metal complexes. Likely complexes to form during these reactions are 
RuCl2(DMSO)2L
1 
and RuCl(DMSO)3L
2
, but others are also possible. It was also attemped 
to react HL
2
 with RuCl3,  
A ligand similar to HL
2
, containing two Schiff-base nitrogens, had previously been 
synthesized and used in a ruthenium(III) complex.
11
 There are also examples of ruthenium(II) 
complexes with DMSO and a ligand containing two Schiff bases in the reported by Khan et. 
Al.
12
 (Figure 10). However, all these examples includes ligands with two Schiff bases, while 
HL
2
 contains only one and L
1
 none. 
It was however not attempted to synthesize the complex to the lower left in Figure 10 since it 
seemed that all the products containing ruthenium were insoluble in most solvents and was 
therefore hard to analyze.  
 
Figure 10.  A complex with Ru(III) synthesized by Khan et al (upper left) and a complex with Ru(II) 
synthesized by Chatterjee et al (upper right) in comparison to complexes with L
2
 that was likely to form 
during the reactions with Ru(III) and Ru(II). X in the upper right complex is DMSO.  
  
                                                          
11
 Chatterjee, D.; Mitra, A. Journal of Coordination Chemistry 2004 57:3 175-182  
12
 Khan, N. H.; Pandya, N.; Kureshy, R. I.; Abdi, S. H. R.; Agrawal, S.; Bajaj, H. C.; Pandya, J.; Gupte, A. 
Spectrochimica Acta Part A 74 2009 113–119  
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Rhodium 
Three rhodium starting materials were used: RhCl3xH2O, where rhodium has the oxidation 
number 2, the dimer [Rh(COD)Cl]2, where rhodium is in the +1 oxidation state and COD 
stands for cyclo-octadien, and Rh(CO)3Cl where rhodium has +3 as oxidation state. 
Rh(CO)3Cl were obtained by treating RhCl3xH2O with DMF and it was then used in attempts 
of synthesizing new metal complexes. [Rh(CO)2]L
2
 and [Rh(CO)L
1
]Cl are possible products 
of this reaction. This route has been successfully carried out to form similar metal complexes 
by Oro et. Al.
13
 (Figure 10). In addition some HL
2
 was reduced by NaBH4 to form HL
3
 which 
also was reacted in the same way. A probable complexes to form by these reaction is 
[Rh(CO)2]L
3
. The conversion of HL
2
 into HL
3
 was confirmed by 
1
H-NMR spectroscopy, 
and the conversion was made in order to avoid possible hydrolysis of the ligand 
 
 
Figur 11. Example of a salicealdehyde-Rh(I) complex synthesized  by Oro et al which was synthesized by treating RhCl3 
with DMF followed by addition of a bidentate ligand (upper left)  in comparison to complexes with L
1
 (upper right), HL
2
 
(lower left) and HL
3
 (lower right) that was likely to form during similar reactions in DMF.  Since rhodium has the oxidation 
state of  +1 the complexes are square planar.  
 
 
 
 
                                                          
13
Valderrama, M.; Oro, L. A. Journal of Organometallic Chemistry 1981, 218, 241. 
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The most effort in this project was spent on attempts to synthesize new metal complexes by 
reacting L
1
 and HL
2 
with the dimer [Rh(COD)Cl]2 . The idea was to split the dimer 
[Rh(COD)Cl]2  into two monomers and add a stoichiometric amount of equivalent ligand.  
[Rh(COD)L
1
]
+
 and Rh(COD)L
2
 are complexes that are likely to form by this reaction. 
Similar complexes to Rh(COD)L
2
 have been synthesized by Saed et Al
14
 by reacting the 
ligand and Rh2(COD)2Cl2 in DCM and adding a solution of KOH in water, and this strategy 
was attempted with L
2
. Comparison of the complexes is shown in Figure 11. 
                         
Figure 12. Comparison of a complex synthesized by Saed et al (left) and a complex that would likely form 
when L
2
 is reacted with [Rh(COD)Cl]2 (right). 
 
Metroni et. Al.
15
 reported that similar complexes to [Rh(COD)L
1
]
+ 
(see Figure 12) can be 
made by reacting the ligand and Rh-dimer in MeOH without the addition of base, and then 
add NH4PF6 to precipitate the product. A combination of the two methods of Saed et al and 
Meteroni et al was used in the attempt to synthesize complexes that likely have the structure. 
[Rh(COD)L
1 
]
+
and Rh(COD)L
2
. Since no NH4PF6 was available AgPF6 was used instead. 
 
Figure 13. Comparison of the type of molecules reported by Meteroni et. Al. and the desired complex (1) (Rh(COD)L
1
)
+
 
that we attempted to synthesize. 
                  
                                                          
14
 Saeed, I.; Shiotsuki, M.; Masuda, T.; Journal of Molecular Catalysis A: Chemical 254 2006 124–130 
 
15
 Zassinovich, G.; Camus, A.; Mestroni, G. Journal of Organometallic Chemistry, 133 1977 377-384 
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Rhenium 
The starting material for the attempted rhenium reactions Re(CO)5Br, which was obtained by 
treating the dimer (Re(CO)5)2 with Br2 following a standard procedure
16
 and an attempt was 
made to form the complexes Re(CO)3BrL
1
 and Re(CO)4L
2
 by reacting Re(CO)5Br with L
1
 
or L
2
. 
 
Results and discussion 
Ligand synthesis 
L’ was synthesized following the procedure used in the Nordlander Group, except 5 
equivalents of ethylene diamine was used instead of two. Increasing the amount of ethylene 
diamine made the solution less viscous and easier to handle. The reaction led to the formation 
of a white byproduct that was insoluble in DCM and partly soluble in water. This had to be 
filtered of before the washing steps were done with the separation funnel, otherwise the funnel 
would clog. The byproduct was probably formed when the L’ reacted with 4,7-
dichloroquinoline, forming N,N’-di(7-chloroquinoline-4-yl)ethane-1,2-diamine. This structure 
was however not confirmed, since the byproduct was insoluble in the solvents used for 
1
HNMR analysis. Due to the formation of byproduct, the overall yield was only 23.1 %. 
 
Scheme 1. Synthesis of L’. Reagents and conditions: i) NH2(CH2)2NH2 5 eq, 80 °C for 1 hour and 130 °C for 12 hours.   
 
 
Figure 14. Proposed structure of the byproduct that forms during the synthesis of L’. The structure of the byproduct was 
not confirmed.  
The three ligands L
1
, HL
2
 and HL
3
 were synthesized according to Scheme 2, 3 and 4. The 
synthesis of and HL
2
 had previously been described
3
 while L
1
 and HL
3
 has been synthesized 
                                                          
16
 Angelici, R. J. Inorganic Synthesis vol 28, 1990 , ISBN 0-471-52619-3, also 
http://onlinelibrary.wiley.com/doi/10.1002/9780470132593.ch42/summary;jsessionid=0A27676D0DCE0DA842
F06051E806240C.f03t01 Jan 2015. 
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in our laboratory (unpublished work). Good yields were obtained for all three ligands (L
1 
89.7 %, 
, HL
2
 85.6%, HL
3
 87.3%). 
The first step in the synthesis of L
1  
(Scheme 2) was to make pyrzinoic acid chloride by 
reacting pyrzinoic acid with thionyl chloride. This had already been made by a lab worker, but 
since the acid chloride was purple it had to be purified, which was done by sublimation. This 
yielded a white powder of pyrzinoic acid chloride, which was suspended in DCM at 0 °C and 
a suspension of L’ was added dropwise. The low temperature and slow addition of L’ was to 
prevent unwanted side reactions.  
When HL
2
 first was synthesized it was realized that a small amount of the salicylaldehyde did 
not reacted, as could be seen in the 
1
H-NMR spectrum. The unreacted aldehyde could easily 
be removed by putting the product under vacuum on the Shlenk line and heating to 80 °C for 
4 h, but that left some unreacted L
’
 in the product. It was therefore decided to use some excess 
of aldehyde to make sure that all L
’
 was converted to HL
2
, and always heat the product to 80 
°C under vacuum before the purity was checked by 
1
H-NMR. Two reactions were done 
following this procedure and both yielded the desired product in high yield (89.7 %) without 
any impurities.  
HL
3 
is a reduced form of HL
2
, which was made in one step by reacting HL
2
 with NaBH4. 
1
H-
NMR of HL
3
 showed that all reactants had been consumed, which means that any loss of 
product must be due to the washing step. The washing was made in order to remove the side 
products NaBH3 and NaOH. HL
3
 was only used in one unsuccessful experiment due to lack 
of time. 
 
Scheme 2. Conditions for the synthesis of L
1
. i) DCM, 0 
o
, 1 h and then washing with hexane. 
15 
 
 
 
        
Scheme 3.  Conditions for the synthesis of HL
2
 i) EtOH, reflux overnight followed by removal of excess 
aldehyde at 80 Cᴼ, vacuum 2-4 h. 
 
 
 
  
Scheme 4. Conditions for the synthesis of HL
3
 i) NaBH4, MeOH, 25°C, 10 min.  
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Ruthenium complexes 
Since it seemed that all the products containing ruthenium were insoluble in most solvents 
only a few reaction were made with this metal. In total 7 different reactions were carried out, 
but the tested combinations of RuCl2(DMSO)4 or RuCl3xH2O  with L
1
 or HL
2
 always lead to 
a product that was always a blackish solid that could not be analyzed by NMR. It could 
therefore not be said if any of the desired complexes (6), (7), (8), or (9) ( RuCl2(DMSO)2L
1
 , 
(RuCl3xH2O)L
1
, RuCl1(DMSO)3L
2
 and RuCl1(DMSO)3L
2
 ) were obtained. TLC indicated 
that some reactions had occurred, but since it was not possible to tell what the outcome had 
been it was decided to focus on other metals instead of Ru. TLC indicated that usually three 
different products + the starting materials remained after the reactions, but these were hard to 
distinguish. For example, when preparative TLC was made during an attempted synthesis of 
(6) ( RuCl2(DMSO)2L
1
 ) the product could not be analyzed by 
1
H-NMR due to insufficient 
solubility. It was not soluble in water, MeOH, acetone, benzene or DMSO. 
 
Figure 15. The desired ruthenium complexes RuCl2(DMSO)2L
1
 (upper left) , (RuCl3xH2O)L
1
 (upper right), RuCl1(DMSO)3L
2
 
 
(lower left). None of these complexes were successfully synthesized and characterized. Note: all possible isomers are not 
represented in the picture.  
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In the attempted synthesis of RuCl(DMSO)3L
2
 the 
1
H-NMR showed a very distinct peak at 9 
ppm, which corresponds to an aldehyde proton. An explanation for this peak is that the ligand 
has been hydrolyzed, forming the amine and aldehyde from which it was synthesized 
(Scheme 5). Hydrolytic cleavage of Shiff bases by Ru(II) has been documented by Sakanya 
et. Al.
17
 and Mahalingam et. Al
18
, which unfortunately was discovered after the attempted 
reactions  had been carried out. The experiments in this project, along with the results of 
Sakanya et. Al. and Mahalingam et. Al. concludes that it is not possible to attach HL
2
 to 
Ru(II) without causing hydrolysis, and it seems best to put the effort on different experiments  
in order to come up with a useful anti malaria agent. In comparison to the successful 
synthesized ruthenium complex by Khan et. Al. it seems that a ligand needs to have at least 2 
Schiff-base nitrogens in order to not be hydrolyzed by Ru(II). 
 
 
Scheme 5. Attempted synthesis of complex (9).  Reagents and conditions: (i) 1 eq RuCl2(DMSO)4, MeOH. This rout was 
confirmed to not work. Different stereoisomers for the desired product are not represented. 
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 Sakanya, D.; Evans, R. M.; Zeller, M.; Natarajan, K. Polyhedron 26 2007 4314–4320 
18
 Mahalingam, V.; Chitrapriya, N.; Fronczek, F. R.; Natarajan, K. Polyhedron 29 2010 3363–3371 
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Rhodium complexes 
Lots of effort was made in the attempt synthesizing [Rh(COD)L
1
]
+ 
 (1) and Rh(COD)L
2
 (2) 
using (Rh(COD)Cl)2 as starting materials, since Meteroni et. Al. have reported very similar 
complexes. One attempt was also made to synthesize Rh(COD)L
3
 (11). As in the case with 
ruthenium the solubility of the product remained an issue: it was not soluble in common 
deuterated solvents used for NMR. It was however realized that it could be dissolved in a 
mixture of 70:30 CDCl3:MeOH-d4. The mixture also contained TMS as reference. For 
comparison, the 
1
H-NMR spectra of the starting materials was measured in the same solvent 
mixture.  
It was seen that no product (1, Rh(COD)L
1  
), was formed when the reaction was carried out 
in DCM or MeOH  at -80 °C, but that some was formed when the same reaction was run at 
room temperature. The amount of product formed was determined by comparing the size of 
the peaks corresponding to starting material and the size of the peaks corresponding to 
product in the 
1
H-NMR spectra. It was realized that more activation energy was needed for 
complete conversion of starting material to product. The reaction was then carried out in 
refluxing MeOH (10 % product), refluxing EtOH (60% product) and refluxing DMF (no 
NMR result). It was reasoned that the high activation energy was needed to break the dimer 
bonds in (Rh(COD)Cl)2 in order to make it react. To investigate this 0.9 eq AgPF6 was added 
to a reaction mixture of 0.5 eq Rh2(COD)2Cl2 and 1 eq L
1
 or 1 eq HL
2
 in MeOH. Even though 
the reactions were run at room temperature almost all the starting materials was converted to 
product. The same experiments were then repeated using 1.1 eq AgPF6, and all the starting 
materials was converted, forming either crystals of 1 (blood red) or 2 (dark yellow).  The 
1
H-
NMR spectra for 2 was not fully clean and the product needs further purification, and spectra 
of 1 indicated that it was pure.  Scheme 6 shows the successful routes used for the syntheses. 
 
Scheme 6. Probably successful syntheses of the complexes [L
1
Rh(COD)][PF6] (1) and L
2
Rh(COD) (2). i) DCM, RT, 10 min ii) 
addition of 1.1 eq AgPF6 in MeOH, mixing at RT overnight.  
1 
2 
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The fully reaction that likely yields 1, [L
1
Rh(COD)][PF6], is described in Figure 11: The 
silver ions react with the dimer to form AgCl, which is the precipitate that is seen in the 
reaction mixture. While the dimer is split free nothing prevents the ligand from interact with 
it, and a metal complex can form.  Any silver ion could be used, but the advantage of AgPF6 
(in comparison to for example AgNO3) is that the hexaflourophosphate  ion makes crystal 
formation of the product more likely to occur. Crystal formation is important since good 
quality crystals are needed for x-ray crystallography. 
Regrettably the yields were not calculated for these two complexes, and the synthetic route 
was not optimized due to lack of time. About 40 mg reactant was used, and to get sufficient 
1
H-NMR spectra 10 mg is needed, so one can assume that the yields were 25% at the very 
least, but probably much higher since all reactant seemed to have reacted when interpreting 
the NMR spectra. It is possible that the route could have been simplified, for example by 
mixing all the reactants at once and using a shorter reaction time. The presumable successful 
synthesis was carried out by first dissolving (Rh(COD)Cl)2 and L
1 
or HL
2
 in DCM and then 
add a solution of 1.1 eq AgPF6 in MeOH. Due to lack of time no simplification of the routes 
were tested, and no further attempt to synthesize (11) was made.  
 
 
 
Scheme 7. The assumed complete reaction in the synthesis of 1, [L
1
Rh(COD)][PF6]. 
 
 
 
1 
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Figure 16. Structure of the complex 10, the L
3
 equivalent of complex 2. Synthesis of 10 was not attempted to 
due to lack of time. 
The synthesis of  (11), (Rh(CO)3Cl) L
2
,  was attempted in a number of ways, since a similar 
compound have been described by Oro et. Al. As described in this paper, RhCl3xH2O was 
refluxed in DMF to form Rh(CO)3Cl. The color of the mixture went from red to amber, 
indicating Rh(CO)3Cl had formed. L
2
 was then added to the solution was stirred for 1 h before 
water was added to make the product precipitate. Since it did not precipitate the pH was 
adjusted to 10 and the solution was left in the freezer overnight, and a small amount of 
precipitate was formed. The solution was then centrifuged and a red-brown powder was 
obtained. It was insoluble in water, MeOH, CDCl3 and DMSO, so no 
1
HNMR could be 
performed. 
 The same experiment was repeated without adjusting the pH, since it was believed that this 
might hydrolyze the ligand HL
2
. The red-brown precipitate that was collected after 
centrifugation could now be dissolved in MeOD. 
1
H-NMR showed an aromatic compound 
with only four different shifts in the aromatic region, indicating that the ligand had been 
cleaved despite the neutral pH. It was reasoned that the C=N bond in L
2
 had been hydrolyzed 
as in the case with the Ru(II), and that L’ was in the supernatant and salicylaldehyde in the 
precipitate. To confirm this the supernatant was also analyzed. A small amount of an 
unknown aromatic compound plus some aldehyde was found. No conclusion can be drawn 
from this data, but the fact that the spectrum of the precipitate did not contain as many signals 
as expected for the ligand indicate that L
2
 had been cleaved. 
The same experiment was repeated once again under water free conditions, to prevent any 
hydrolysis during the synthesis.  All glass ware was dried in an oven over night, dry DMF 
was used and EtOAc (70 mL) was used to form the precipitate. One advantage was that the 
density of EtOAc is 0.9 kg/L, which made sedimentation much faster compared to when 
water was used. When EtOAc had been added the opaque mixture was left in the fridge over 
the weekend and the supernatant could then be decanted from the precipitate. Again the 
1
H-
NMR only showed 4 different peaks corresponding to the same molecule in the aromatic 
region, indicating that HL
2
 had been hydrolyzed despite the water free environment in which 
the reaction was performed. 
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Scheme 8. Atempted synthesis of complex 11. Reagents and conditions: (i) DMF, 154 
o
 C, 1 hour, (ii) L
2
, DMF, room temp, 
1 hour. This route did not give the desiered product.  
In a last attempt, HL
2
 was reduced to HL
3
, using NaBH4, and the same experiment was 
repeated using this new ligand in an attempt to form Rh(CO)2L
3
, complex 12. EtOAc was 
used to precipitate the product of the reaction, but not enough could be collected to run 
1
H-
NMR despite that 100 mL EtOAc was used and the mixture was stored in the freezer over 
weekend to get as much precipitate as possible. It was then decided to not attempt any more 
reactions that included DMF as a solvent. The mayor drawback with DMF is its high boiling 
point of 154 °C; the solvent is hard to remove in vacuo
 
and the product is easier obtained by 
precipitation, which in this case showed to be a bit to challenging. 
Due to lack of time it was not tested to reflux RhCl3xH2O in DMF to form Rh(CO)3Cl and 
then react it with L
1
, which might have given complex 13. 
       
Figure 17. Rh(CO)2L3 (complex 12) that was not successfully synthesized and [Rh(CO)2L1][Cl] (complex 13) 
that was not attempted to synthesize due to lack of time.   
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Rhenium complexes 
Two rhenium complexes Re(CO)3BrL
1
 (4)  and Re(CO)4L
2
 (5) is believed to have been 
synthesized, using Re(CO)5Br (3) as starting the material. The exact molecular formula of 
these were not determined due to lack of time, but there are good reasons to believe that they 
formed: no trace of the staring material Re(CO)5Br  could be seen by IR spectroscopy, but 
instead new carbonyl peaks appeared. This indicates that all the starting material was 
consumed, and therefore that the product was formed.  KBr was used since 4 and 5 were not 
soluble in DCE or DCM, solvents which were used for IR analysis. The spectra of 3 in KBr 
showed peaks corresponding to CO at 1964, 2035 and 2060. The supposed product 
L
1
Re(CO)3Br showed signals at 2019, 1903, 1884, 1602 and 1565. Since none of the signals 
from the starting material remains it is most likely that L
1
 has coordinated with the metal. The 
product when HL
2
 was reacted with 3 showed strong IR signals at 2010, 1906, 1882 and 
1592. Again the same argument applies; The signals have changes in comparison to the 
starting material, so it is likely that the ligand has coordinated. 
The 1H-nmr of 4 agrees with the proposed formulation, peaks of L
1
 was shifted in such a way 
that it indicates coordination of Re through the oxygen and nitrogen of L
1
. 
 
No 
1
H-NMR could be obtained of Re(CO)4L
2
 due to low solubility in common deuterated 
solvents. It was not determined if rhenium coordinated to the lone pair of the Schiff base 
nitrogen, which is drawn in Scheme 10.  One way to have done this would have been to take 
IR spectra of the ligands L
1
 and HL
2
 and compare with those of the product. If rhenium is 
coordinated to the amide nitrogen in complex 4 the N=O stretching frequency would probably 
be affected, so if the corresponding signals for this bond differs between L
1
 and complex 4 it 
would be indicated that the proposed structure in Scheme 10 is correct.    
If the metal is coordinated to the Schiff base nitrogen in complex 5 it would probably change 
the C=N stretching frequency in HL
2
, so a change at this signal would confirm the proposed 
structure. However, it might be hard to observe the C=N signal in HL
2 
since the quinoline 
part of the molecule also has IR absorption in the same region. One can also look for changes 
in the region in which the O-H bond of the alcohol part of HL
2
 gives rise to signals.  
The reason why one the complex with L
1 
is thought to have a bromine coordinated to the 
metal while the complex with [L
2
]
-
 does not is because of the oxidation state of Re(I). If one 
assumes that Re does not change its oxidation number the bromine needs to be kept to forma a 
neutral complex when L
1
 is coordinated, since L
1
 is a neutral ligand. [L
2
]
-
 on the other hand is 
a charged ligand, and the thus the bromine needs to leave in order for Re(II) to keep its 
oxidation state. This reasoning assumes however that the complexes are neutral. It is possible 
that they instead are charged, so that 4 has the formula [Re(CO)4L
1
]
+
[Br]
-
 and (5) the formula 
[Re(CO)4L
2
Br]
-
[ [Et3NH]
+
. Since the complexes were much less soluble in water than 
DMSO it is however believed that they are neutral. Crystallography or mass spectrometry are 
examples of methods that could be used in order to determine this. 
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Scheme 9. Synthesis of Re(CO)5Br (complex 3) from [Re(CO)4]2 (3). 1 eq Br2, dried DCM, N2 atmosphere. 
 
 
Scheme 10. Synthesis of the complexes L
1
Re(CO)3Br (4) and Re(CO)4L
2 
(5). Conditions for Complex 4: i) DCE, 
reflux 48 hours. Conditions for Complex 5: i) 1.5 eq Et3N, DCE ii) reflux 48 hours. 
  
5                         
4 
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Conclusions 
 
Ruthenium complexes                 
None of the desired complexes 6 – 9 ( RuCl2(DMSO)2L
1
 , (RuCl3xH2O)L
1
 , 
RuCl1(DMSO)3L
2
 or (RuCl2xH2O)L
2
 ) could successfully be synthesized. It was realized 
that Ru(II) hydrolyses Schiff bases such as HL
2
, and that these two molecules cannot be 
combined to form a metal complex. Overall, reactions of L
1
 or HL
2 
with ruthenium tend to 
form black, insoluble solids that are hard to characterize. Since they not seem to be soluble in 
anything it is not likely that they would be able to penetrate a malaria parasites food vacuole. 
It would also be challenging to administrate a drug based on these complexes and measure the 
anti-malaria activity in vitro, and it is therefore unlikely that they would work as anti-malaria 
agents.   
 
Rhodium complexes 
The complexes 1 and 2 ( [Rh(COD)L
1
][PF6] and Rh(COD)L
2
 ) were successfully 
synthesized by splitting the Rh(COD)Cl2 dimer using AgPF6. The synthesis gave pure 1 while 
2 needs further purification. Even though these to complexes might not work as anti-malaria 
agents the synthetic route could still be valuable. It is likely that more complexes with similar 
ligands, Rh(COD)L
x
, can be made by using this strategy. New metal complexes like these 
might be useful in medicine, or as catalysts in chemical reactions. 
 
 
Rhenium complexes 
Two rhenium complexes 4 and 5 ( Re(CO)3BrL
1
 and Re(CO)4L
2
 ) is believed to have been 
synthesized. The exact characterization and coordination of these was not made due to lack of 
time, and the yields were also not calculated. However, it was confirmed that rhenium 
carbonyl complexes that include L
1
 or HL
2
 can be synthesized following the described route, 
and it is most likely that other similar ligands also can be used to make up these kinds of 
complexes. 
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Experimental 
All chemicals were used as received unless anything else is noted. The 
1
H-NMR spectra were 
recorded on a Varian Inova 500 spectrophotometer at 500 MHz and the IR spectra recorded 
on a Nicolet Avatar 360 FT-IR instrument. 
Successful experiments 
N-(7-chloroquinoline-4-yl)ethane-1,2-diamine (L’) 
4-7-dichloroquinoline (4.62 g, 23 mmol) and ethylene diamine (4670 µl, 70 mmol, 3 eq) were 
heated to 80 °C for one h before heating to 130 °C overnight. The resulting slurry was diluted 
with DCM (1000 mL), filtered and the filtrate was washed with water, 5% NaHCO3, again 
with water and finally brine before drying over MgSO4 and concentrated in vacuo yielding L’ 
as an off-white solid (1190 mg, 23.1 % yield). H
1
-NMR: 2.80(t 2H), 3.24(q, 3H), 6.48(d 1H), 
7.22(t 1H) 7.43(1H dd) 
 
N-(7-chloroquinoline-4-yl)ethane-1,-amino-2-amido-pyrazine, (L
1
) 
Pyrzinoic acid chloride was purified by sublimation and 142 mg (2mmol) was suspended at 0 
°C in DCM (10 mL) in a two necked flask fitted with an additional funnel. 7-chloro-
4,quinoline)ethylamine, L’, (416 mg, 2 mmol, 1 eq) was suspended in DCM and added 
dropwise during 1 h via the addition funnel. A pink precipitate formed which was filtered of 
and washed with hexane to yield L
1
. (614 mg, 89.7% yield). 
1
H-NMR (DMSO –d6): 3.64(q 
2H) 3.72( q 2H) 7.01(d 1H) 8.56(d 1H), 8.72(t 1H), 8.87(d 1H), 9.16(d 1H), 9.26(t 1H). 
 
 
N-(-2((2-hydroxyphenyl)methylimino)ethyl)-7-chloroquinolin-4-amine (HL
2
) 
 N-(7-chloroquinoline-4-yl)ethane-1,2-diamine, L’, (198 mg, 1 mmol) and salicylaldehyde 
(97 µL, 1.1 mmol, 1.1 eq) were refluxed in EtOH (10 mL) over night, concentrated in vacuo 
and put under vacuum at 80 °C for 4 hours to yield HL2 as a yellow powder (260 mg, 85.6% 
yield. 
1
H-NMR: (CDCl3/MeOH-d4, 70:30): 3.68(t 1H) 3.30 (t 1H), 3.88(t 2H) 6.45(d 1H) 
6.82 (t 1H) 6.89(d 1H), 7.15( dd 1H), 7.27 (d 1H) 7.29(t 1H), 7.32 (s 1H),  7.76(d 1H), 7.81(d 
1H), 8.37(d H1), 9.00(s 1H),  
 
 
N-(-2((2-hydroxyphenyl)methylamino)ethyl)-7-chloroquinolin-4-amine (HL
3
) 
HL
2
 (126 mg, 0.4 mmol) and NaBH4 (30 mg, 0.8 mmol, 2 eq) were dissolved in MeOH (40 
mL) at 25 °C, stirred for 10 min, concentrated in vacou, dissolved in DCM, washed 3 times 
with water and concentrated in vacuo to yield HL
3 
as an agar colored (yellow-beige) powder 
(110 mg, 87.3% yield). . 
1
H-NMR: (CDCl3) showed that the product was pure, but the shift 
signals were not saved properly and therefore not collected. 
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η -2-( N-(7-chloroquinoline-4-yl)ethane-1,-amino-2-amido-pyrazine)-hapto-4-
cyclooctadien-rhodium hexaflourophosphate, (1)                    
L
1
 (22 mg, 70 µmol) and [Rh(COD)Cl]2 (17 mg, 35 µmol, 0.5 eq) were dissolved in DCM (2 
mL) and stirred at 25
o
 C for 30 min. AgPF6 (19 mg, 77 µmol, 1.1 eq) was dissolved in MeOH 
(1 mL) and added to the DCM solution, which instantly made a dark red precipitate form. The 
solution was stirred at 25°C overnight, filtered through a 0.45 µm propylene filter and 
concentrated in vacuo to yield [Rh(COD)L
1
][PF6] as blood red crystals. No yield was 
calculated. 
1
H-NMR (CDCl3/MeOH-d4, 70:30): 3.43(t 2H), 3.31(s 1H), 3.62(t 2H), 4.10(s 
1H), 4.41(s 2H) 7.78(d 1H), 7.62(d 1H), 7.68 (s 1H), 7.73(d 1H), 8.17(d 1H), 8.19 (s, 1H), 
8.83(d 1H), 9.21(s 1H)  
 
η- 2-( N-(-2((2-hydroxyphenyl)methylamino)ethyl)-7-chloroquinolin-4-amine) (hapto-4-
cyclooctadien-rhodium (2)                                                                                                    
HL
2
 (23 mg, 70 µmol) and [Rh(COD)Cl]2 (17 mg, 35 µmol) were dissolved in DCM (3 mL) 
and stirred at 25
o
 C for 30 min. AgPF6 (19 mg, 7.7 mmol, 1.1 eq) was dissolved in MeOH (1 
mL) and added to the DCM solution which instantly made a dark red precipitate form. Et3N 
(12µL, 100 µmol, 1.5 eq) was added and the mixture was stirred overnight, washed with 
water and concentrated in vacuo to yield Rh(COD)L
2
 as dark yellow crystals. No yield was 
calculated. The product did not generate a clear 
1
H-NMR spectra in CDCl3/MeOH-d4 70:30 
or DMSO-d6, but it indicated that the product had formed. 
 
Reniumpentacarbonylbromid (3) 
Re2(CO)10 (200 mg, 3 mol) was dissolved in dry DCM (5 mL) in a dried schlenk tube under 
N2. The solution was titrated with Br2 (approximately 10 µL) until it changed from colorless 
to brown by using a syringe that penetrated the septa of the schlenk tube. The solution was 
concentrated on the schlenk line at 30 °C to yield Re(CO)5Br as white crystals. No yield was 
calculated. IR (KBr): 1964, 2035, 2060. 
 
η -2-( N-(7-chloroquinoline-4-yl)ethane-1,-amino-2-amido-pyrazine)-tris-carbonyl--
bromo-renium (4)                                                                                    
L
1
 (22 mg, 70 µmol) and Re(CO)5Br (24 mg, 70 µmol, 1 eq) were refluxed in DCE for 4 
hours and an IR specra was taken of the solution and compared with a spectra for pure DCE. 
No change were observed and the mixture was refluxed for 48 hours which made an orange-
yellow precipitate form that was filtered of to yield Re(CO)3BrL
1
. No yield was calculated. 
IR (KBr): 2019, 1903, 1884, 1602, 1565. 
1
H-NMR (CDCl3/MeOH-d4, 70:30): 2.53(t 1H),  
3.62(t 1H), 3.70(s 1H, 3.88 (t 1H), 3.90(s 2H) 6.64(t 1H), 7.65(s 1H), 8.00(d 1H), 8.25(t 1H), 
8.89(t 1H), 9.18(s 1H),  
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η -2-( N- N-(-2((2-hydroxyphenyl)methylamino)ethyl)-7-chloroquinolin-4-amine) tris-
carbonyl--bromo-renium (5)                  
HL
2
 (21 mg, 70 µmol), Re(CO)5Br (24 mg, 70 µmol, 1 eq) and Et3N (11 µL, 100 µmol, 1.5 
eq) were refluxed in DCE for 4 hours and an IR specra was taken of the solution and 
compared with a spectra of pure Re(CO)5Br in DCE. No change were observed and the 
mixture was refluxed for 48 hours which made a green-yellow precipitate to form that was 
filtered of and washed with DCM:MeOH 80:20 to yield Re(CO)4L
2
. No yield was calculated. 
IR (KBr): 2010, 1906, 1882, 1592, weak: 1611, 1536, 1445. No sufficient NMR data was 
obtained due to low solubility. 
   
Examples of unsuccessful experiments 
 
η -2-( N-(7-chloroquinoline-4-yl)ethane-1,-amino-2-amido-pyrazine)-ruthenium-
dichloro-di-(dimethylsulphoxide) (6) 
L
1
 (47 mg, 140µmol) and RuCl2(DMSO)4 (71 mg, 140 µmol, 1 eq) was refluxed in 50:50 
MeOH/DCM overnight and concentrated on a rotor vap, yielding a blackish solid that was 
almost insoluble in common solvents. It was purified by prep TLC (70:29:1 
DCM/MeOH/Et3N) but no sufficient NMR results were obtained due to low solubility in 
CDCl3, D2O, d-DMSO, d-benzene and d-MeOH. 
 
η -2-( N-(7-chloroquinoline-4-yl)ethane-1,-amino-2-amido-pyrazine)-ruthenium-
trichloride-monohydrate (7) 
L
1
 (50 mg, 150 µmol), RuCl3xH2O (82 mg, 150 µmol, 1 eq) and NaOH (10 mg, 250 µmol, 
excess) were refluxed in MeOH for 2 hours, yielding a black precipitate that was not soluble 
in any of the solvents in the lab. 
 
η -2-( N- N-(-2((2-hydroxyphenyl)methylamino)ethyl)-7-chloroquinolin-4-amine)-
ruthenium- dichloride-dihydrate (8) 
HL
2
 (32 mg, 99 µmol), RuCl3xH2O (53 mg, 99 µmol) and Et3N (28 µl, 200 µmol) was stirred 
in MeOH (20 mL) for 3 hours at room temperature. The reactants did not dissolved and the 
MeOH was evaporated, water (20 mL) and and Et3N (28 µl, 200 µmol) was added and the 
mixture was refluxed for 1 h and then stirred at room temperature over night. The mixture 
went from brown to blackish. TLC (MeOH and a few drops Et3N as eluent) indicated that 
reaction had occurred but no NMR was made due to bad solubility. 
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η -2-( N- N-(-2((2-hydroxyphenyl)methylamino)ethyl)-7-chloroquinolin-4-amine)-
ruthenium-tetra-(dimethylsulphoxide)-chloride (9) 
HL
2
 (24 mg, 72 µmol), RuCl2(DMSO)4 (35 mg, 72 µmol) and Et3N (20 µl, 140 mmol, 2 eq) 
were mixed in MeOH overnight. The mixture went from yellow to amber in 10 minutes and 
amber to black in 2 hours. TLC (99:1 MeOH/Et3N) indicated that reaction had occurred, the 
solution was concentrated in vacuoto to yield a black solid. No sufficient NMR results were 
obtained due to bad solubility, but hydrolysis of HL
2
 was indicated. 
 
η -2-( N- N-(-2((2-hydroxyphenyl)methylamino)ethyl)-7-chloroquinolin-4-amine)-
rhodium-dichloride-hydrate (11) 
RhCl3xH2O (22 mg, 84 µmol) was dissolved in DMF (7 ml), refluxed for 1 h and cooled to 
ambient temperature before HL
2
 (27 mg, 84 µmol, 1 eq) was added and the mixture stirred for 
2 h. It was then diluted with water and stored in a refrigerator overnight, centrifuged at 400 
rpm for 30 min, the supernatant removed, water added, again centrifuged for 10 min and the 
yellow pellet collected and dried in vacuo and analyzed by 
1
H-NMR.  Too small amount of 
the product was collected to get a clear spectra, but it indicated that hydrolysis of HL
2
 had 
occurred.  
η -(2-N-(-2((2-hydroxyphenyl)methylamino)ethyl)-7-chloroquinolin-4-amine)-rhodium-
dichloride-hydrate (12) 
RhCl3xH2O (25 mg, 96 µmol) was dissolved in DMF (7 ml), refluxed for 1 and cooled to 
ambient temperature before HL
3
 (27 mg, 84 µmol, 1 eq) was added and the mixture stirred for 
2 h. EtOAc (100 mL) was added and the mixture stored in a refrigerator over the weekend 
yielding a yellow precipitate that was collected. Not enough could be collected to get an 
useful  
1
H-NMR spectrum. 
η -2-( N-(7-chloroquinoline-4-yl)ethane-1,-amino-2-amido-pyrazine)-hapto-4-
cyclooctadien-rhodium chloride (1) 
HL
1
 (55 mg, 170 µmol) and [ Rh(COD)Cl]2 (41 mg, 85 µmol, 0.5 eq) was dissolved in DCM 
(4 ml) and stirred at 25°C over night. TLC (DCM/MeOH 80:20) showed that no reaction had 
occurred. 
η -2-( N-(7-chloroquinoline-4-yl)ethane-1,-amino-2-amido-pyrazine)-hapto-4-
cyclooctadien-rhodium (2) 
HL
2
 (28 mg, 87 µmol) and [RhCl(COD)]2
 
(22 mg, 44 µmol, 2 eq) was dissolved in DCM (4 
mL), KOH ( 15 µg, excess) in water (5 mL) was added and the suspension stirred at 25 °C for 
6 hours before the aqueous  phase was removed and the organic phase dried with MgSO4 and 
concentrated in vacuo. 
1
H-NMR indicated hydrolysis of HL
2
 and the formation of some 
unknown product.  
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Populärvetenskaplig sammanfattning 
 
Det här kandidatarbetet gick ut på att syntetisera ett antal olika ämnen som i efterhand ska 
testas för att se om de kan användas i en malariamedicin. Arbetet fokuserade således på att 
beskriva sjukdomen malaria, olika ämnen som skulle kunna fungera som medicin och 
slutligen hur dessa ämnen kan tillverkas. Det innehåller dessutom beskrivningar av några 
tillvägagångssätt som inte fungerar vid tillverkning av de här ämnena. 
Malaria är en sjukdom som orsakas av en parasit (en encelligt eukaryot) som via myggstick 
kommer in i människan. I kroppen bryter den ner röda blodkroppar, vilket leder till symptom 
såsom feber och smärta, och i värsta fall kan en malariainfektion leda till döden. När 
malariaparasiten bryter ner hemoglobin ifrån de röda blodkroparna frisätts haem, ett 
järninehållande ämne som är en del av hemoglobin och som är giftigt för parasiten. Detta sker 
i en så kallad födovakuol, en speciell blåsa i parasiten som fungerar som dess mage. I 
födovakuolen klumpas haemet ihop till en ogiftig, fast form.  
Klorokin är en gammal malariamedicin verkar genom att tränga in i födovakuolen och hindra 
att järnet klumpar ihop sig, vilket leder till att parasiten dör av haemförgiftning. Tyvärr har 
många parasiter på senare år utvecklat en födovakuol med en cellvägg som gör att klorokinet 
transporteras ut så fort det kommer in, vilket gör parasiterna klorokinresistenta. Det finns idag 
även en annan typ av medicin, artemesinin, men parasiterna börjar utveckla resistans mot den 
också. Enligt Världshälsoorganisationen är ett av de största problemen med malaria att 
parasiterna utvecklar resistens, och det är därför viktigt att utveckla nya mediciner.   
Ämnena som tillverkades under kandidatarbetet påminner om klorokin men innehöll också en 
metall, vilket förhoppningsvis ska göra att de fungerar på parasiter med en utvecklad 
födovakuol. Det finns idag ett nyutvecklat ämne som heter ferrokin, vilket påminner om en 
klorokinmolekyl som är kopplad till en järnatom. Ferrokin kan döda malariaparasiter även om 
de har en utvecklat klorokinresistans, men ämnet är så pass ny att det ännu inte används som 
medicin eftersom det fortfarande forskas på det. Detta visar dock att en gammal icke-
fungerande medicin kan fungera igen om den görs om så att den innehåller en metall.  
Att en medicin innehåller metall är en ganska ny idé, det finns idag endast ett fåtal mediciner 
som gör det. Eftersom det förmodligen finns så mycket nytt att upptäcka är det därför ett 
spännande område att utforska inom kemin. 
Under arbetet testades att sammanfoga metallerna rutenium, rodium och renium men några 
organiska molekyler som påminner om klorokin. Resultatet blev att totalt fyra olika molekyler 
som inte tidigare har gjorts tillverkades: Två som innehöll rodium och två som innehöll 
renium. Dessa kommer förhoppningsvis att kunna testas för att se om de biter på 
malariaparasiter med klorokinresistans. Inga fungerande sätt att tillverka specifika molekyler 
som innehöll rutenium hittades. En anledning till detta är att rutenium kunde bilda många 
olika föreningar på en gång då det reagerades med en organisk molekyl. Dessutom 
katalyserade rutenium nedbrytandet av vissa molekyler som metallen var tänkt att bilda 
föreningar med.    
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